Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

Abstract Background Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10–20% of metastatic urothelial carcinomas and confer sensitivity to FGFR inhibitors. However, responses to these agents are often short-lived due to the development of acquired resistance. The objectiv...

Full description

Bibliographic Details
Main Authors: Andrew J. Weickhardt, David K. Lau, Margeaux Hodgson-Garms, Austen Lavis, Laura J. Jenkins, Natalia Vukelic, Paul Ioannidis, Ian Y. Luk, John M. Mariadason
Format: Article
Language:English
Published: BMC 2022-05-01
Series:BMC Cancer
Subjects:
Bladder cancer
FGFR3
EGFR
ERBB2
ERBB3
Targeted therapy
Online Access:https://doi.org/10.1186/s12885-022-09478-4

Internet

https://doi.org/10.1186/s12885-022-09478-4

Similar Items